- Home
- PGEN vs INVA Comparison
PGEN vs INVA Comparison
Compare PGEN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | INVA |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PGEN | INVA |
|---|---|---|
| Price | $5.55 | $23.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $8.33 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 5.5M | 750.3K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 2.22 |
| Revenue | ★ $230,981,000.00 | $217,217,000.00 |
| Revenue This Year | $1,115.92 | $8.95 |
| Revenue Next Year | $81.04 | $12.65 |
| P/E Ratio | ★ N/A | $10.65 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $1.40 | $16.52 |
| 52 Week High | $5.61 | $25.15 |
Technical Indicators
Market Signals| Indicator | PGEN | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 74.63 | 62.62 |
| Support Level | $4.00 | $23.28 |
| Resistance Level | N/A | $24.22 |
| Average True Range (ATR) | 0.32 | 0.60 |
| MACD | 0.15 | 0.17 |
| Stochastic Oscillator | 96.70 | 74.12 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.